Skip to main content

immune checkpoint inhibitors

News
06/19/2020
Tumor mutation burden (TMB), BRCA1/2 mutations, and homologous DNA repair deficiency (HRD) are not associated with immune checkpoint inhibitor response or survival in recurrent ovarian cancer, according to an...
Tumor mutation burden (TMB), BRCA1/2 mutations, and homologous DNA repair deficiency (HRD) are not associated with immune checkpoint inhibitor response or survival in recurrent ovarian cancer, according to an...
Tumor...
06/19/2020
Journal of Clinical Pathways
Research Reports
06/18/2019
Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-small cell lung cancer (amNSCLC). There is an unmet need...
Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-small cell lung cancer (amNSCLC). There is an unmet need...
...
06/18/2019
Journal of Clinical Pathways